McKesson Corporation MCK

McKesson Corporation se enfoca en la distribución de productos farmacéuticos y en proporcionar tecnología de información de salud, suministros médicos y herramientas de gestión de cuidados. Los segmentos de la compañía incluyen Farmacéutico de EE. UU., Internacional, Soluciones Médico-Quirúrgicas y Soluciones Tecnológicas de Prescripción (RxTS). El segmento Farmacéutico de EE. UU. proporciona servicios de distribución y logística para medicamentos farmacéuticos de marca, genéricos, especializados, biosimilares y de venta libre, así como otros productos relacionados con la salud. El segmento Internacional ofrece distribución y servicios a clientes mayoristas, institucionales y minoristas en 13 países europeos y Canadá. El segmento de Soluciones Médico-Quirúrgicas proporciona distribución de suministros médico-quirúrgicos, logística y otros servicios a proveedores de atención médica. El segmento RxTS combina sus tecnologías, incluyendo CoverMyMeds, RelayHealth, RxCrossroads y McKesson Prescription Automation, para servir a sus socios de biofarmacia y ciencias de la vida, así como a los pacientes.

Con 1 acción de MCK (USD 913,64) habrías recibido USD 3,40 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex

  The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026.

  

• Zacks Investment Research 2 oct

  Company News for Oct 2, 2026

  Several major companies reported quarterly earnings with mixed results. Accenture surged 15.8% after beating earnings estimates, while McKesson gained 5.3% on maintained guidance. Conversely, Acuity fell 3.4% and Progress Software dropped 8.5% after missing revenue expectations.

  

• Zacks Investment Research 1 oct

  5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve

  The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR. However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets.

  

• Zacks Investment Research 30 sept

  McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know

  McKesson closed down 1.27%, underperforming the S&P 500's 0.25% loss. The stock has declined 4.63% over the past month, lagging the Medical sector. The company is expected to report earnings on November 4, 2026, with projected EPS growth of 8.72% and revenue growth of 6.78% year-over-year. McKesson holds a Zacks Rank of #3 (Hold) with a Forward P/E of 19.37, trading at a premium to its industry average.

  

• Zacks Investment Research 29 sept

  Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

  McKesson raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00 following strong Q1 results with 20% EPS growth. The company is benefiting from robust growth in oncology services, specialty distribution, and GLP-1 therapies, which generated $15 billion in Q1 revenues. However, headwinds include branded drug price declines, generic conversion pressure, and regulatory uncertainty around 340B reform and IRA Part D changes.